These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 2113401)

  • 21. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
    Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
    Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The fibrinolytic system in neoplasia.
    Bell WR
    Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
    Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
    Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
    Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V; Pannell R; Broeze RJ; Mao J
    J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intraglomerular coagulation and fibrinolysis in human primary glomerular diseases].
    Shibata K; Dohi K; Fujii Y; Ishikawa H
    Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):719-29. PubMed ID: 1770632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
    Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O
    Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haemostasis in oral surgery--the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system.
    Sindet-Pedersen S
    Dan Med Bull; 1991 Dec; 38(6):427-43. PubMed ID: 1802633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Changes in systemic fibrinolysis and blood coagulation parameters in local thrombolysis with tissue plasminogen activator (rt-PA)].
    Klein P; Roth FJ; Rieger H; Popov-Cenic S
    Vasa; 1992; 21(3):249-52. PubMed ID: 1529628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
    Tomaru T; Uchida Y; Sonoki H; Tsukamoto M; Sugimoto T
    Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
    Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
    Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasminogen activators and their potential in therapy.
    Hollander IJ
    Crit Rev Biotechnol; 1987; 6(3):253-71. PubMed ID: 3146436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.